RS66922B1 - Kristalni oblici metil (s)‑2‑((2‑(2,6-difluoro‑4‑(metilkarbamoil)fenil)‑7-metilimidazo[1,2-a]piridin‑3-il)metil)morfolin‑4-karboksilata modulatora p2x3 - Google Patents
Kristalni oblici metil (s)‑2‑((2‑(2,6-difluoro‑4‑(metilkarbamoil)fenil)‑7-metilimidazo[1,2-a]piridin‑3-il)metil)morfolin‑4-karboksilata modulatora p2x3Info
- Publication number
- RS66922B1 RS66922B1 RS20250594A RSP20250594A RS66922B1 RS 66922 B1 RS66922 B1 RS 66922B1 RS 20250594 A RS20250594 A RS 20250594A RS P20250594 A RSP20250594 A RS P20250594A RS 66922 B1 RS66922 B1 RS 66922B1
- Authority
- RS
- Serbia
- Prior art keywords
- crystalline form
- methyl
- type
- theta
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760307P | 2018-11-13 | 2018-11-13 | |
| EP19884611.5A EP3880678B1 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate |
| PCT/IB2019/001199 WO2020099923A1 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66922B1 true RS66922B1 (sr) | 2025-07-31 |
Family
ID=70732059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20250594A RS66922B1 (sr) | 2018-11-13 | 2019-11-12 | Kristalni oblici metil (s)‑2‑((2‑(2,6-difluoro‑4‑(metilkarbamoil)fenil)‑7-metilimidazo[1,2-a]piridin‑3-il)metil)morfolin‑4-karboksilata modulatora p2x3 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220002292A1 (https=) |
| EP (1) | EP3880678B1 (https=) |
| JP (2) | JP2022507251A (https=) |
| CN (1) | CN113302191A (https=) |
| AU (1) | AU2019378161B2 (https=) |
| CA (1) | CA3119711A1 (https=) |
| DK (1) | DK3880678T3 (https=) |
| ES (1) | ES3033466T3 (https=) |
| FI (1) | FI3880678T3 (https=) |
| HR (1) | HRP20250864T1 (https=) |
| HU (1) | HUE071480T2 (https=) |
| IL (1) | IL282996A (https=) |
| LT (1) | LT3880678T (https=) |
| MX (1) | MX2021005424A (https=) |
| PL (1) | PL3880678T3 (https=) |
| PT (1) | PT3880678T (https=) |
| RS (1) | RS66922B1 (https=) |
| SI (1) | SI3880678T1 (https=) |
| SM (1) | SMT202500237T1 (https=) |
| WO (1) | WO2020099923A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL282087B2 (en) * | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| JP7578602B2 (ja) * | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| EP4169921A4 (en) * | 2020-06-29 | 2024-06-19 | Wuhan LL Science and Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2025140586A1 (zh) * | 2023-12-29 | 2025-07-03 | 人福医药集团股份公司 | 一种p2x3受体拮抗剂的固体分散体及其制备工艺 |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2025210540A1 (en) | 2024-04-02 | 2025-10-09 | Assia Chemical Industries Ltd. | Solid state forms of camlipixant and process for preparation thereof |
| WO2026022326A1 (en) * | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
| JP2026049185A (ja) | 2024-09-06 | 2026-03-18 | キヤノン株式会社 | 撮像装置、撮像方法、及びコンピュータプログラム |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3381917T3 (da) * | 2013-01-31 | 2021-10-18 | Bellus Health Cough Inc | Imidazopyridinforbindelser og anvendelser deraf |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
-
2019
- 2019-11-12 HR HRP20250864TT patent/HRP20250864T1/hr unknown
- 2019-11-12 FI FIEP19884611.5T patent/FI3880678T3/fi active
- 2019-11-12 EP EP19884611.5A patent/EP3880678B1/en active Active
- 2019-11-12 CN CN201980088914.9A patent/CN113302191A/zh active Pending
- 2019-11-12 US US17/292,663 patent/US20220002292A1/en active Pending
- 2019-11-12 ES ES19884611T patent/ES3033466T3/es active Active
- 2019-11-12 LT LTEPPCT/IB2019/001199T patent/LT3880678T/lt unknown
- 2019-11-12 PT PT198846115T patent/PT3880678T/pt unknown
- 2019-11-12 JP JP2021525726A patent/JP2022507251A/ja active Pending
- 2019-11-12 SI SI201930943T patent/SI3880678T1/sl unknown
- 2019-11-12 SM SM20250237T patent/SMT202500237T1/it unknown
- 2019-11-12 HU HUE19884611A patent/HUE071480T2/hu unknown
- 2019-11-12 WO PCT/IB2019/001199 patent/WO2020099923A1/en not_active Ceased
- 2019-11-12 CA CA3119711A patent/CA3119711A1/en active Pending
- 2019-11-12 MX MX2021005424A patent/MX2021005424A/es unknown
- 2019-11-12 AU AU2019378161A patent/AU2019378161B2/en active Active
- 2019-11-12 DK DK19884611.5T patent/DK3880678T3/da active
- 2019-11-12 PL PL19884611.5T patent/PL3880678T3/pl unknown
- 2019-11-12 RS RS20250594A patent/RS66922B1/sr unknown
-
2021
- 2021-05-06 IL IL282996A patent/IL282996A/en unknown
-
2024
- 2024-07-05 JP JP2024109053A patent/JP2024153665A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3880678T (pt) | 2025-05-22 |
| MX2021005424A (es) | 2021-06-15 |
| EP3880678A1 (en) | 2021-09-22 |
| CN113302191A (zh) | 2021-08-24 |
| JP2022507251A (ja) | 2022-01-18 |
| AU2019378161A1 (en) | 2021-06-03 |
| SI3880678T1 (sl) | 2025-08-29 |
| EP3880678A4 (en) | 2022-08-31 |
| AU2019378161B2 (en) | 2025-01-30 |
| LT3880678T (lt) | 2025-06-25 |
| HRP20250864T1 (hr) | 2025-09-26 |
| EP3880678B1 (en) | 2025-05-07 |
| HUE071480T2 (hu) | 2025-08-28 |
| WO2020099923A1 (en) | 2020-05-22 |
| FI3880678T3 (fi) | 2025-08-01 |
| IL282996A (en) | 2021-06-30 |
| US20220002292A1 (en) | 2022-01-06 |
| PL3880678T3 (pl) | 2025-08-04 |
| DK3880678T3 (da) | 2025-06-10 |
| JP2024153665A (ja) | 2024-10-29 |
| SMT202500237T1 (it) | 2025-07-22 |
| CA3119711A1 (en) | 2020-05-22 |
| ES3033466T3 (en) | 2025-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3880678B1 (en) | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate | |
| JP7350117B2 (ja) | Ｍａｇｌ阻害剤の結晶形態 | |
| JP2023022224A (ja) | 固定用量製剤 | |
| JP6670841B2 (ja) | フェノール酸ｔｒｐｖ１アゴニストのプロドラッグ | |
| CN110840845A (zh) | 一种包含parp抑制剂的药物组合物 | |
| JP2025026857A (ja) | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 | |
| WO2004054574A1 (ja) | 経口固形医薬 | |
| JP2022510303A (ja) | 痛風または高尿酸血症を処置または予防するための方法 | |
| CA2983446A1 (en) | Bromodomain inhibitor | |
| JP2021532183A (ja) | フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ | |
| EP3675865B1 (en) | Crystalline forms of compounds for preventing or treating sensory hair cell death | |
| WO2017107857A1 (zh) | 一种含有二胺衍生物或其盐的固体药物组合物 | |
| RU2799564C2 (ru) | Кристаллические формы ингибитора magl | |
| HK40069310A (en) | A crystalline form of a magl inhibitor | |
| WO2026085383A1 (en) | Crystalline forms of an nlrp3 modulator | |
| JP2007297348A (ja) | エバスチンを含有する錠剤 | |
| HK40009165A (en) | A crystalline form of a magl inhibitor |